Summary & Overview
CPT 87635: Laboratory Detection of SARS-CoV-2 via Nucleic Acid Amplification
CPT code 87635 represents the laboratory detection of SARS‑CoV‑2, the virus responsible for COVID-19, using nucleic acid amplification methods. This code is a cornerstone of national COVID-19 testing strategies, enabling rapid identification of infection and supporting public health efforts. The procedure is typically performed in laboratory or office settings and is widely recognized by major payers, including Aetna, Blue Cross Blue Shield, Cigna Health, and UnitedHealthcare.
This publication provides a comprehensive overview of 87635, including payer coverage, clinical context, and policy updates relevant to laboratory infectious agent detection. Readers will gain insight into coding benchmarks, reimbursement trends, and the role of this code in COVID-19 screening and diagnosis. The analysis also highlights associated modifiers, provider taxonomies, and related codes, offering a clear understanding of how 87635 fits within broader laboratory billing practices. As COVID-19 continues to impact healthcare delivery, understanding the nuances of this code is essential for stakeholders across the industry.
CPT Code Overview
CPT code 87635 is used for the detection of severe acute respiratory syndrome coronavirus 2 (SARS‑CoV‑2), the virus responsible for COVID-19, through nucleic acid amplification techniques. This laboratory service identifies the presence of viral DNA or RNA, providing critical information for diagnosing COVID-19. The typical site of service for this procedure is a laboratory (POS 81) or an office setting (POS 11). This code is central to COVID-19 testing protocols and supports timely clinical decision-making during the ongoing public health response.
Clinical & Coding Specifications
Clinical Context
A patient presents to a healthcare provider's office or a laboratory with symptoms suggestive of COVID-19, such as fever, cough, or shortness of breath, or has had known exposure to someone with COVID-19. The provider orders a laboratory test to detect the presence of SARS-CoV-2 using an amplified probe technique. The specimen, typically a nasopharyngeal swab, is collected and sent to a laboratory (Place of Service 81) or performed in the office (Place of Service 11). The laboratory uses nucleic acid amplification to detect viral RNA, and the results inform clinical management, isolation protocols, and public health reporting.
Coding Specifications
- Modifier
QW: Indicates that the test performed is CLIA-waived, meaning it is approved for use in settings with a Certificate of Waiver under the Clinical Laboratory Improvement Amendments. This modifier is used when the laboratory or office is performing a test that meets CLIA waiver criteria.
| Modifier Code | Description |
|---|---|
QW | CLIA-waived test performed |
- Provider Taxonomies:
6J: This taxonomy represents providers who offer testing for COVID-19. It is applicable to laboratories and clinical providers who perform SARS-CoV-2 testing.
Related Diagnoses
-
U07.1: COVID-19, virus identified- Used when laboratory confirmation of COVID-19 is present. Relevant for patients with a positive SARS-CoV-2 test.
-
Z20.822: Contact with and (suspected) exposure to COVID-19- Used for patients who have been exposed or suspected to have been exposed to COVID-19, often prompting testing.
-
J12.82: Pneumonia due to coronavirus disease 2019- Used when a patient has pneumonia confirmed to be caused by COVID-19, supporting the need for SARS-CoV-2 testing.
-
Z11.52: Encounter for screening for COVID-19- Used for patients undergoing screening for COVID-19 without symptoms or known exposure.
-
Z86.16: Personal history of COVID-19- Used for patients with a documented history of COVID-19, relevant for follow-up or surveillance testing.
Related CPT Codes
-
U0003: Crosswalk:U0003(high‑throughput SARS‑CoV‑2 nucleic acid detection)- Used for high-throughput testing platforms that detect SARS-CoV-2 RNA. This code is related to
87635and may be used as an alternative when high-throughput methods are employed.
- Used for high-throughput testing platforms that detect SARS-CoV-2 RNA. This code is related to
-
U0002: HCPCS codeU0002(non‑CDC SARS‑CoV‑2 testing)- Used for SARS-CoV-2 testing that is not performed using CDC-developed methods. This code is related to
87635and may be used in clinical workflows where non-CDC tests are utilized.
- Used for SARS-CoV-2 testing that is not performed using CDC-developed methods. This code is related to
These codes may be used together or as alternatives depending on the testing methodology and platform used. 87635 is commonly used for standard nucleic acid detection, while U0003 and U0002 are used for specific high-throughput or non-CDC testing scenarios.
National Reimbursement Benchmarks
For CPT code 87635, the national mean rate for BUCA (average commercial) payers is $51.61, which is higher than the UnitedHealth Group mean rate of $48.64. Among the commercial payers, Aetna has the highest mean rate at $57.20, while Cigna and Blue Cross Blue Shield are closely aligned at $50.58 and $50.99, respectively.
Rate dispersion, measured by the difference between the 75th and 25th percentiles, varies significantly across payers. Cigna exhibits the widest spread at $37.00, indicating substantial variability in reimbursement rates. In contrast, UnitedHealth Group shows the tightest range at $20.00, suggesting more consistent rates nationally. Aetna, Blue Cross Blue Shield, and BUCA fall in between, with ranges of $9.33, $20.67, and $14.83, respectively.
The table and chart below present the full breakdown of national benchmarks for CPT code 87635 across major commercial payers.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.